Revisiting iron overload status and change thresholds as predictors of mortality in transfusion-dependent β-thalassemia: a 10-year cohort study.
Heart
Iron chelation
Iron overload
Liver
MRI
Serum ferritin
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
received:
08
02
2024
accepted:
15
03
2024
medline:
20
3
2024
pubmed:
20
3
2024
entrez:
20
3
2024
Statut:
aheadofprint
Résumé
Data on iron overload status and change thresholds that can predict mortality in patients with transfusion-dependent β-thalassemia (TDT) are limited. This was a retrospective cohort study of 912 TDT patients followed for up to 10 years at treatment centers in Italy (median age 32 years, 51.6% female). The crude mortality rate was 2.9%. Following best-predictive threshold identification through receiver operating characteristic curve analyses, data from multivariate Cox-regression models showed that patients with Period Average Serum Ferritin (SF) > 2145 vs ≤ 2145 ng/mL were 7.1-fold (P < 0.001) or with Absolute Change SF > 1330 vs ≤ 1330 ng/mL increase were 21.5-fold (P < 0.001) more likely to die from any cause. Patients with Period Average Liver Iron Concentration (LIC) > 8 vs ≤ 8 mg/g were 20.2-fold (P < 0.001) or with Absolute Change LIC > 1.4 vs ≤ 1.4 mg/g increase were 27.6-fold (P < 0.001) more likely to die from any cause. Patients with Index (first) cardiac T2* (cT2*) < 27 vs ≥ 27 ms were 8.6-fold (P < 0.001) more likely to die from any cause. Similarly, results at varying thresholds were identified for death from cardiovascular disease. These findings should support decisions on iron chelation therapy by establishing treatment targets, including safe iron levels and clinically meaningful changes over time.
Identifiants
pubmed: 38503936
doi: 10.1007/s00277-024-05715-x
pii: 10.1007/s00277-024-05715-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Chouliaras G, Berdoukas V, Ladis V, Kattamis A, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Karagiorga-Lagana M (2011) Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. J Magn Reson Imaging 34:56–59
pubmed: 21608067
doi: 10.1002/jmri.22621
Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ (2008) Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 10:42
pubmed: 18817553
pmcid: 2563008
doi: 10.1186/1532-429X-10-42
Forni GL, Gianesin B, Musallam KM, Longo F, Rosso R, Lisi R, Gamberini MR, Pinto VM, Graziadei G, Vitucci A, Bonetti F, Musto P, Piga A, Cappellini MD, Borgna-Pignatti C, Webthal P (2023) Overall and complication-free survival in a large cohort of patients with beta-thalassemia major followed over 50 years. Am J Hematol 98:381–387
pubmed: 36588408
doi: 10.1002/ajh.26798
Nichols-Vinueza DX, White MT, Powell AJ, Banka P, Neufeld EJ (2014) MRI guided iron assessment and oral chelator use improve iron status in thalassemia major patients. Am J Hematol 89:684–688
pubmed: 24652616
pmcid: 5752110
doi: 10.1002/ajh.23715
Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ, Thalassemia Clinical Research N (2012) Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood 119:2746–2753
pubmed: 22279056
pmcid: 3327453
doi: 10.1182/blood-2011-04-344507
Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ (2011) On T2* magnetic resonance and cardiac iron. Circulation 123:1519–1528
pubmed: 21444881
pmcid: 3435874
doi: 10.1161/CIRCULATIONAHA.110.007641
St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105:855–861
pubmed: 15256427
doi: 10.1182/blood-2004-01-0177
Hankins JS, McCarville MB, Loeffler RB, Smeltzer MP, Onciu M, Hoffer FA, Li CS, Wang WC, Ware RE, Hillenbrand CM (2009) R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 113:4853–4855
pubmed: 19264677
pmcid: 2686136
doi: 10.1182/blood-2008-12-191643
Kirk P, He T, Anderson LJ, Roughton M, Tanner MA, Lam WW, Au WY, Chu WC, Chan G, Galanello R, Matta G, Fogel M, Cohen AR, Tan RS, Chen K, Ng I, Lai A, Fucharoen S, Laothamata J, Chuncharunee S, Jongjirasiri S, Firmin DN, Smith GC, Pennell DJ (2010) International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging 32:315–319
pubmed: 20677256
pmcid: 2946327
doi: 10.1002/jmri.22245
Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, Coates TD (2005) MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 106:1460–1465
pubmed: 15860670
pmcid: 1895207
doi: 10.1182/blood-2004-10-3982
Wood JC, Zhang P, Rienhoff H, Abi-Saab W, Neufeld E (2014) R2 and R2* are equally effective in evaluating chronic response to iron chelation. Am J Hematol 89:505–508
pubmed: 24452753
doi: 10.1002/ajh.23673
St Pierre TG, El-Beshlawy A, Elalfy M, Al Jefri A, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Taher A (2014) Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. Magn Reson Med 71:2215–2223
pubmed: 23821350
doi: 10.1002/mrm.24854
Cappellini MD, Farmakis D, Porter J, Taher A, Guidelines for the management of transfusion dependent thalassaemia (TDT). 4th ed. 2021, Nicosia, Cyprus: Thalassaemia International Federation.
Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR (1994) Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331:574–578
pubmed: 8047081
doi: 10.1056/NEJM199409013310903
Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89:1187–1193
pubmed: 15477202
Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B (2000) Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 110:971–977
pubmed: 11054091
doi: 10.1046/j.1365-2141.2000.02298.x
Daar S, Al Khabori M, Al Rahbi S, Hassan M, El Tigani A, Pennell DJ (2020) Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up. Ann Hematol 99:2009–2017
pubmed: 32556452
doi: 10.1007/s00277-020-04117-z
Olivieri NF, Brittenham GM (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89:739–761
pubmed: 9028304
doi: 10.1182/blood.V89.3.739
Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, Ripalti M, Sodani P, Tomassoni S, Visani G, Lucarelli G (2002) Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100:17–21
pubmed: 12070002
doi: 10.1182/blood.V100.1.17
Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22:2171–2179
pubmed: 11913479
doi: 10.1053/euhj.2001.2822
Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennell DJ (2009) Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120:1961–1968
pubmed: 19801505
pmcid: 2784198
doi: 10.1161/CIRCULATIONAHA.109.874487
Carpenter JP, Roughton M, Pennell DJ, Iron M, in Thalassemia I, (2013) International survey of T2* cardiovascular magnetic resonance in beta-thalassemia major. Haematologica 98:1368–1374
pubmed: 23812939
pmcid: 3762092
doi: 10.3324/haematol.2013.083634
Ambati SR, Randolph RE, Mennitt K, Kleinert DA, Weinsaft JW, Giardina PJ (2013) Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2* in patients with thalassemia major on various chelation regimens: a 6-year study. Am J Hematol 88:652–656
pubmed: 23640778
pmcid: 4030379
doi: 10.1002/ajh.23469
Kamperidis V, Vlachou M, Pappa Z, Pantelidou D, Karamitsos T, Papadopoulou D, Kartas A, Boutou A, Ventoulis I, Vlachaki E, Giannakoulas G, Karvounis H (2021) Prediction of long-term survival in patients with transfusion-dependent hemoglobinopathies: Insights from cardiac imaging and ferritin. Hellenic J Cardiol 62:429–438
pubmed: 33524617
doi: 10.1016/j.hjc.2021.01.010
Bayraktaroglu S, Karadas N, Onen S, Karapinar DY, Aydinok Y (2022) Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study. Ann Hematol 101:521–529
pubmed: 34985558
doi: 10.1007/s00277-021-04748-w
Danjou F, Origa R, Anni F, Saba L, Cossa S, Podda G, Galanello R (2013) Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment. Blood Cells Mol Dis 51:142–145
pubmed: 23816436
doi: 10.1016/j.bcmd.2013.06.001
Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC (2008) Longitudinal analysis of heart and liver iron in thalassemia major. Blood 112:2973–2978
pubmed: 18650452
pmcid: 2556627
doi: 10.1182/blood-2008-04-148767
Musallam KM, Taher AT, Cappellini MD, Hermine O, Kuo KHM, Sheth S, Viprakasit V, Porter JB (2022) Untreated Anemia in Nontransfusion-dependent beta-thalassemia: Time to Sound the Alarm. Hemasphere 6:e806
pubmed: 36407091
pmcid: 9668557
doi: 10.1097/HS9.0000000000000806
Vitrano A, Musallam KM, Meloni A, Karimi M, Daar S, Ricchi P, Costantini S, Vlachaki E, Di Marco V, El-Beshlawy A, Hajipour M, Ansari SH, Filosa A, Ceci A, Singer ST, Naserullah ZA, Pepe A, Cademartiri F, Pollina SA, Scondotto S, Dardanoni G, Bonifazi F, Sankaran VG, Vichinsky E, Taher AT, Maggio A, International Working Group on T (2023) Development of a Thalassemia International Prognostic Scoring System (TIPSS). Blood Cells Mol Dis 99:102710
pubmed: 36463683
doi: 10.1016/j.bcmd.2022.102710
Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT (2012) Serum ferritin levels and endocrinopathy in medically treated patients with beta thalassemia major. Ann Hematol 91:1107–1114
pubmed: 22281991
doi: 10.1007/s00277-012-1412-7
Bassett ML, Halliday JW, Powell LW (1986) Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 6:24–29
pubmed: 3943787
doi: 10.1002/hep.1840060106
Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107:3455–3462
pubmed: 16352812
doi: 10.1182/blood-2005-08-3430
Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, Taher AT (2011) Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica 96:1605–1612
pubmed: 21791471
pmcid: 3208677
doi: 10.3324/haematol.2011.047852
Sonakul D, Thakerngpol K, Pacharee P (1988) Cardiac pathology in 76 thalassemic patients. Birth Defects Orig Artic Ser 23:177–191
pubmed: 3390539
Link G, Pinson A, Hershko C (1985) Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med 106:147–153
pubmed: 4020242
Nathan DG (2005) Thalassemia: the continued challenge. Ann N Y Acad Sci 1054:1–10
pubmed: 16339645
doi: 10.1196/annals.1345.001
Taher AT, Cappellini MD (2018) How I manage medical complications of beta-thalassemia in adults. Blood 132:1781–1791
pubmed: 30206117
doi: 10.1182/blood-2018-06-818187
Aessopos A, Fragodimitri C, Karabatsos F, Hatziliami A, Yousef J, Giakoumis A, Dokou A, Gotsis ED, Berdoukas V, Karagiorga M (2007) Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica 92:131–132
pubmed: 17229649
doi: 10.3324/haematol.10455
Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E (2007) Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 92:583–588
pubmed: 17488680
doi: 10.3324/haematol.10842
Taher A, El Rassi F, Isma’eel H, Koussa S, Inati A, Cappellini MD (2008) Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 93:1584–1586
pubmed: 18728025
doi: 10.3324/haematol.13098
Vitrano A, Calvaruso G, Tese L, Gioia F, Cassara F, Campisi S, Butera F, Commendatore V, Rizzo M, Santoro V, Cigna V, Quota A, Bagnato S, Argento C, Fidone C, Schembari D, Gerardi C, Barbiera F, Bellisssima G, Giugno G, Polizzi G, Rosso R, Abbate G, Caruso V, Chiodi E, Gamberini MR, Giorgi B, Putti MC, Filosa A, De Ritis MR, Oliva E, Arcadi N, Fustaneo M, Mistretta L, Di Maggio R, Sacco M, Veronica DS, Giangreco A, Maggio A (2016) Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET. Eur J Haematol 97:361–370
pubmed: 26818147
doi: 10.1111/ejh.12740
Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, Young NS, Allen CJ, Farrell DE, Harris JW (1993) Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 42:81–85
pubmed: 8416302
doi: 10.1002/ajh.2830420116
Vitrano A, Sacco M, Rosso R, Quota A, Fiorino D, Oliva E, Gerardi C, Roccamo G, Spadola V, Filosa A, Tese L, Calvaruso G, Pitrolo L, Mistretta L, Cassara F, Di Maggio R, Maggio A (2018) Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET. Eur J Haematol 100:124–130
pubmed: 29094403
doi: 10.1111/ejh.12989
Voskaridou E, Douskou M, Terpos E, Papassotiriou I, Stamoulakatou A, Ourailidis A, Loutradi A, Loukopoulos D (2004) Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol 126:736–742
pubmed: 15327528
doi: 10.1111/j.1365-2141.2004.05104.x
Piga A, Longo F, Musallam KM, Cappellini MD, Forni GL, Quarta G, Chiavilli F, Commendatore F, Mulas S, Caruso V, Galanello R (2013) Assessment and management of iron overload in beta-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project. Br J Haematol 161:872–883
pubmed: 23600689
doi: 10.1111/bjh.12340
Di Tucci AA, Matta G, Deplano S, Gabbas A, Depau C, Derudas D, Caocci G, Agus A, Angelucci E (2008) Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 93:1385–1388
pubmed: 18603557
doi: 10.3324/haematol.12759
Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennell DJ (2006) Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 8:543–547
pubmed: 16755844
doi: 10.1080/10976640600698155
Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD (2010) The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 116:537–543
pubmed: 20421452
doi: 10.1182/blood-2009-11-250308
Puliyel M, Sposto R, Berdoukas VA, Hofstra TC, Nord A, Carson S, Wood J, Coates TD (2014) Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. Am J Hematol 89:391–394
pubmed: 24347294
doi: 10.1002/ajh.23650
Porter JB, Elalfy M, Taher A, Aydinok Y, Lee SH, Sutcharitchan P, El-Ali A, Han J, El-Beshlawy A (2017) Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia. Eur J Haematol 98:280–288
pubmed: 27859648
doi: 10.1111/ejh.12830
Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G (2000) Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 343:327–331
pubmed: 10922422
doi: 10.1056/NEJM200008033430503
Worwood M, Cragg SJ, Jacobs A, McLaren C, Ricketts C, Economidou J (1980) Binding of serum ferritin to concanavalin A: patients with homozygous beta thalassaemia and transfusional iron overload. Br J Haematol 46:409–416
pubmed: 7448126
doi: 10.1111/j.1365-2141.1980.tb05987.x
Viprakasit V, Ajlan A, Aydinok Y, Al Ebadi BAA, Dewedar H, Ibrahim AS, Ragab L, Trad O, Wataify AS, Wong LLL, Taher AT (2018) MRI for the diagnosis of cardiac and liver iron overload in patients with transfusion-dependent thalassemia: An algorithm to guide clinical use when availability is limited. Am J Hematol 93:E135–E137
pubmed: 29473204
doi: 10.1002/ajh.25075